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“LIPOPROTEIN (a) IN ISCHEMIC STROKE- A COMPARATIVE STUDY 
BETWEEN TYPE II DIABETIC VS NON DIABETIC PATIENTS” 
ABSTRACT 
AIMS: 
 This study is done to compare lipoprotein (a) level in Type II diabetic and 
non-diabetic patient with ischemic stroke, to know any significant association  
present with lipoprotein (a) levels and ischemic stroke , to identify whether 
diabetic patients have  significantly high lipoprotein (a) value compared non 
diabetic  and to evaluate whether lipoprotein (a) level can use as an  early marker 
to assess severity of ischemic stroke.  
STUDY METHODS: 
     This is a cross sectional study done on 100 patients with ischemic strokewho 
attended Rajiv Gandhi government general hospital over  a period of 6 months 
from June 2013 to November 2013 . Patients with age above 40 years were 
studied. Of the 100 patients studied 50 patients under group 1 weretype II diabetic 
and 50 patients under group 2 were non diabetic. Diagnosis of stroke was made 
clinically and radiologically CT proven .Lipoprotein(a) levels were measured for 
all these patients.The disease morbidity was assessed using the Scandinavian 
scoring system. 
RESULTS AND OBSERVATION: 
    33 patients under group 1(diabetic population) and 23 patients under group 2   ( 
non-diabetic population)  had lipoprotein levels in the high risk category                 
[ Lp(a)= 30 to 50 mg/dl]. There is a significant difference in the association of 
Lp(a) levels and ischemic stroke  p value 0.044 and there is significant association 
between diabetic and non-diabetic population(p value=0.047).The rise in  Lp(a) 
levels to assess the disease severity by Scandinavian scoring system was not 
significant(p value=0.099)  
CONCLUSION : 
High lipoprotein (a) level significantly associated with ischemic stroke. The 
Lp(a) levels were significantly higher inpatients with  type II diabetes than those 
without diabetes. Lp(a) cannot be used as a marker to assess the severity of 
ischemic stroke. 
KEYWORDS: 
        Lipoprotein (a ), typeII diabetics, non-diabetics, Scandinavian score . 
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INTRODUCTION 
Stroke  is defined as rapidly developing clinical signs of focal or global 
disturbance of cerebral function with symptoms lasting for 24 hours or more, it 
is the most common neurological disorder worldwide. Stroke is also known as 
Cerebrovascular Accident (CVA), derived from Greek word which means 
‘Struck Down with violence’1.  
According to the World Health Organization, 15 million people suffer 
from stroke worldwide every year. Of these, 5 million die and another 5 million 
are permanently disabled2. 
Stroke kills more than 1,37,000 people a year, 1 of every 18 deaths. 
Every 40 seconds a stroke occurs every 4 minutes someone dies of stroke . 
The incidence of stroke is higher in men than in women. Every year there 
are about approximately 700,000 cases of stroke, roughly 600,000 ischemic 
lesions and 100,000 hemorrhages, with 175,000 fatalities from these causes.3 
It is estimated that by the year 2020 stroke will become the 4th leading 
cause of disability adjusted life years.4 The prevalence of stroke in India is 
estimated to be 203/100000 population above 20 years of age. The disability 
and morbidity is higher in elderly with doubling of death due to stroke in United 
States by the year 2030.5 
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Cerebrovascular Accident is defined as the abrupt onset of focal 
neurological deficit. It was described as if the patient was struck by the hand of 
God. Stroke may be due to ischemia or hemorrhage, 85% of the stroke are 
ischemic. Occurrence of stroke leads to a lot of physical disability and also 
cognitive and behavioral impairment. The most important risk factors that 
contribute to stroke are Systemic hypertension, Diabetes mellitus, dyslipidemia, 
and Cigarette smoking and heart diseases. These risk factors causing stroke 
when modified and kept under strict control have substantial influence in 
preventing its occurrence and reducing its severity. 
Type 2 diabetes is a major risk factor; dyslipidemia also plays a major 
role as risk factor for ischemic stroke. Studies in the past demonstrated that 
patient with increased lipoprotein (a) and diabetes as risk factor for ischemic 
stroke. High lipoprotein (a) predicts risk of early atherosclerosis independently 
of other risk factor including LDL6 
So here we analyze whether there exists a relationship between 
lipoprotein (a) in type 2 diabetic patients in comparison with non-diabetic 
patients with ischemic stroke, whether lipoprotein (a) can act as an early marker 
or early predictor for worse prognosis in diabetic patients with ischemic stroke 
when compared to non-diabetics. 
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AIMS AND OBJECTIVES 
 
PRIMARY OBJECTIVE:  
To compare lipoprotein (a) level in type 2 diabetic and non-diabetic 
patients with ischemic stroke  
 
SECONDARY OBJECTIVE:  
To evaluate lipoprotein (a) levels as an early marker to assess the severity 
of ischemic stroke in type 2 diabetic patients. 
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REVIEW OF LITERATURE 
 
Stroke  is defined according to the standard WHO clinical criteria as “a 
rapidly developed sign of focal or global disturbance of cerebral function lasting 
longer than 24 hours (unless interrupted by death), with no apparent 
nonvascular cause. 
Stroke is the second leading cause of death worldwide, next to cardiac 
death before cancer accounting for 11% of total death. It is the third most 
common cause for morbidity.                           
From 1990 to 2010, there is a significant decrease in incidence of stroke 
by 12% (95%CI 6-17) in countries of high income and increase in the incidence 
of stroke by 12% in countries with low income and middle income, albeit non 
significantly. There is a significant fall in mortality rates in both high income ( 
37% ,31-41) and low and middle income countries(20%,15-30). In 2010, the 
absolute numbers of people with first stroke (16·9 million), stroke survivors (33 
million), stroke-related deaths (5·9 million), and DALYs lost (102 million) were 
high and had significantly increased since 1990 (68%, 84%, 26%, and 12% 
increase, respectively), with most of the burden (68·6% incident strokes, 52·2% 
prevalent strokes, 70·9% stroke deaths, and 77·7% DALYs lost) in low-income 
and middle-income countries.7 
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 More than 62% of new strokes, 69·8% of prevalent strokes, 45·5% of 
deaths from stroke, and 71·7% of DALYs lost because of stroke were in people 
younger than 75 years.7 
If these trends in stroke incidence, mortality, and DALYs continue, by 
2030 there will be almost 12 million stroke deaths, 70 million stroke survivors, 
and more than 200 million DALYs lost globally.7 
 Stroke occurs more in men than women, elder than younger. 
In India, though only less official records are available stroke and its 
social and economic impact is more worrisome than other developed countries. 
History:    
Hippocrates (460-370BC) is the one who first described the stroke events 
as an acute onset of paralysis. The word stroke used with other meaning of 
Greek word apoplexy  meaning a form of seizure literally means struck down 
with violence was used in 1599 itself.8 
In mid-15thcentury   JOHANN JACOB WEPFER first described people 
who died of bleeding inside brain and he is  one who explained about blood 
supply of brain. 9 
Latter in 1927 term cerebrovascular accidents was introduced and been 
used till now. 
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Stroke may be due to ischemia or hemorrhage.  
85% of all strokes are ischemic. 
 
 
RISK FACTORS  
 The most important risk factor that ranks first in association with stroke is 
Systemic Hypertension. It has been proved that the control of blood 
pressure will decrease the risk of occurrence of stroke in an individual. 
 The other risk factors are 
o Diabetes. 
o Hyperlipidemia. 
o Smoking – Increase the rate of Carotid atherosclerosis 
o Atrial fibrillation – mainly due to cardiac cause. 
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o Infective endocarditis (Bacterial and Nonbacterial) leading on to 
embolic stroke. 
o Right to left shunts 
o Systemic – Hypercoagulable conditions like APLA. 
o Usage of Oral Contraceptive Pills. 
o Symptomatic Carotid Artery Stenosis-70-99% of patients develop 
stroke. 
 
ISCHEMIC STROKE 
Ischemic Stroke refers to occurrence of stroke due to decreased cerebral 
perfusion due to thrombosis or embolism. 
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ETIOLOGY: 
The following table enlists the common and uncommon causes. 
COMMON CAUSES UNCOMMON CAUSES 
Thrombosis Hypercoagulable disorders 
Lacunar stroke (small vessel) Protein C deficiency 
Large vessel thrombosis Protein S deficiency 
Dehydration Antithrombin III deficiency 
Embolic occlusion Antiphospholipid syndrome 
Artery-to-artery Factor V Leiden mutation 
Carotid bifurcation Prothrombin G20210 mutation 
Aortic arch Systemic malignancy 
Arterial dissection Sickle cell anemia 
Cardio embolic Thalassemia 
Atrial fibrillation Polycythemia vera 
Mural thrombus Systemic lupus erythematous 
Myocardial infarction Homocysteinemia 
Dilated cardiomyopathy Thrombotic thrombocytopenic purpura 
Valvular lesions Disseminated intravascular coagulation 
Mitral stenosis Dysproteinemias 
Mechanical valve Nephrotic syndrome 
Bacterial endocarditis Inflammatory bowel disease 
Paradoxical embolus Oral contraceptives 
Atrial septal defect Venous sinus thrombosis 
Patent foramen ovale Fibro muscular dysplasia / Vasculitis 
Atrial septal aneurysm Primary CNS vasculitis 
Spontaneous echo contrast Systemic vasculitis 
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Few rare causes of ischemic stroke include: 
Hypercoagulable disorders:  
A variety of disorders are associated with increased risk of thrombosis. 
Protein C and S deficiency cause arterial thrombosis. SLE, Libman Sacs 
endocarditis causes embolic stroke. Sickle cell anemia is a common cause of 
stroke in children. 
Fibromuscular Dysplasia: 
Fibromuscular   Dysplasia affects the vertebral arteries commonly and is 
more common in women. Usually an incomplete occlusion occurs. Renal artery 
involvement is common and may cause hypertension. Usually asymptomatic but 
may be associated with audible bruit, Stroke. 
Temporal (Giant Cell) Arteritis: 
Temporal (Giant Cell) arteritis is common in old age. Temporal arteries 
undergoes  granulomatous inflammation with giant cells. 
Takayasu Arteritis:  
Takayasu arteritis or idiopathic giant cell arteritis involves the great 
vessels like aortic arch, carotid or vertebral artery leading to thrombosis. 
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MoyaMoya Disease: 
MoyaMoya disease involves the large arteries commonly. The occlusion 
occurs at the stem of Middle Cerebral Artery and Anterior Cerebral Artery. The 
presence of collateral circulation gives the appearance of puff of smoke. 
Reversible Posterior Leukoencephalopathy: 
There is an extensive cerebral segmental vasoconstriction leading to 
cerebral ischemia. The pathophysiology is uncertain but the ischemia is 
reversible completely. 
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Leukoaraiosis: 
Leukoaraiosis or Periventricular white matter disease causes multiple 
small vessel infarcts within the subcortical white matter. It is due to 
lipohyalinolysis of small penetrating arteries. It commonly occurs in chronic 
SHT. 
CADASIL (Cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leucoencephalopathy) most commonly presents as small vessel 
stroke. 
TRANSIENT ISCHEMIC ATTACK (TIA): 
If the neurological signs and symptoms resolve within 1 day (24 hours), 
irrespective of imaging evidence of new brain changes , it’s termed as Transient 
IschemicAttack.10 
One third of TIA occurs in patients with hypertension. They are preceded 
or proceeded by stroke. In 20% of TIA stroke occurs within one month and in 
50% within one year.11 TIA is the warning sign of an impending blood vessel 
occlusion. TIA of longer duration, multiple episodes each with different pattern 
is most probably due to embolism, whereas recurrent brief attacks with similar 
pattern are mostly due to atherosclerosis and thrombosis. 
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TIA can also occur due to increased viscosity of the blood, as in 
hypercoagulable states, polycythemia vera & Leukemia. It occurs most 
commonly in vertebrobasilar system rather than in the carotid system.12 The  
risk of occurrence of myocardial infarction is high after transient ischemic 
attack. 
PATHOPHYSIOLOGY OF ISCHEMIC STROKE: 
The pathophysiology of occurrence of ischemic stroke depends on its 
etiology and risk factors. The pathology may be either due to thrombus or 
embolism or decreased perfusion due to stenosis in arterial system causing 
occlusion. 
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 Altered permeability of vessel wall 
 Change in the viscosity mainly increased viscosity of the blood 
 Blood vessel rupture 
 Atherosclerosis 
 Aneurysmal dilatation 
 Hypertension 
 Arteritis and vasospasm 
 Developmental malfunction. 
 
It is difficult to distinguish the lesion of an embolism or thrombosis. 
Embolic stroke occurs suddenly and the neurological deficit is to the maximum 
at the onset. Thrombotic stroke occurs less abruptly and takes longer time for 
the stroke to evolve. Thrombosis of vessels may lead to artery to artery 
embolism. The stenosis occurs most commonly due to atherosclerosis and 
plaque deposition. 
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Stenosis, Embolism and Thrombosis are shown in this diagram. 
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The extent of ischemia depends on degree and duration of occlusion and 
also the presence or absence of other associated factors like 
• Blood pressure:  
Systemic blood pressure determines the cerebral perfusion pressure. 
When blood pressure is lowered the cerebral perfusion pressure also decreases 
leading to global cerebral ischemia. 
• Hyperthermia:  
Ischemic injury is much severe if there is elevated body temperature. 
• Glucose level: 
Both hypoglycemia and hyperglycemia are associated with a poorer 
outcome. 
• Hypercoagulable state: 
If there is an associated hypercoagulable state there is an increase in micro 
thrombi formation and worsening of blood vessel occlusion. 
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NEURONAL DEATH: 
Neuronal death occurs by two ways: 
• Apoptosis: 
Apoptosis is defined as programmed cell death that occurs in neurons in 
certain conditions like ischemia. The nucleus is damaged first followed by 
activation of suicide proteins in the nuclei that begins the autolytic process 
resulting in cell death. This process is mediated by DNA cleavage. The process 
of apoptosis takes only 1 hour.13 
 
• Coagulation Necrosis: 
Coagulation necrosis is a process by which cell death occurs without 
inflammation. This is due to damage to the plasma membrane by physical and 
chemical stimuli. The cell initially swells then shrinks. This process takes 6-12 
hours to evolve. By 24 hours there is complete necrosis.12 
 
The morphology of cell death in apoptosis is different from cell death due 
to coagulation necrosis.14 
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• Thrombosis: 
Atherosclerosis is the most common pathological cause for the occlusion 
of blood vessel that leads to thrombosis. The plaque that is formed may be 
fractured, ulcerated or calcified. Damage to the endothelium activates 
vasoactive enzymes and releases various factors that contribute to thrombosis 
and occlusion15. 
The other pathological causes of thrombosis is hypercoagulable state by 
formation of clot, micro thrombi that occurs in conditions like Giant cell 
Arteritis, APLA. 
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• Lacunar Infarcts:  
Lacunar Infarct is due to the occlusion of small penetrating arteries 
arising from the cerebral arteries. These may be 100-400 mm in diameter. The 
size of the infarct is about 20mm in diameter. The pathology is due to 
lipohyalinolysis.16,17  The incidence is around 10-30% of all strokes. In people 
with chronic hypertension, the small arterioles are tortuous, long and forms 
micro aneurysm that makes the arteriole susceptible to occlusion. 
• Embolism: 
Embolization of artery may be due to various causes and the most 
common cause is Cardiac source. Most of the emboli occlude the middle 
cerebral artery, because 80% of   blood flow occurs through this artery.18 Apart 
from this the superficial branch of cerebral and cerebellar arteries are involved 
though less frequently. The embolic occlusion can also cause vasospasm by 
acting as an irritant to the blood vessel. Vasospasm   more frequent in younger 
than the elder patients, because blood vessels in younger individuals are not 
much atherosclerotic. 
The important determinants of pale or hemorrhagic infarct are  
a. The size of the infarct  
b. The adequacy of the collaterals 
c. The initiation of therapy like anticoagulants and thrombolysis 
Hypertension is not the independent risk factor for hemorrhagic infarct.19,20 
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• Global Ischemia: 
Global Ischemia is also known as the Hypotensive stroke. Systemic 
hypotension due to any cause can lead to global ischemia. The most commonly 
affected cells are pyramidal cell layer of hippocampus and the purkinje cell 
layer of cerebral cortex. The grey matter in cerebrum is also susceptible to this 
ischemia. It occurs most frequently in the water shed area that is present at the 
junction of anterior, middle and posterior cerebral arteries. 10% of the infarcts 
are water shed infarcts. It occurs due to carotid stenosis in 40%.21 
The clinical presentation of water shed infarct is weakness, sensory 
involvement involving the upper limb more than the lower limb, face is usually 
spared and the speech is not affected. 
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Unlike any other organs, Brain depends entirely on glucose for its 
metabolism as it lacks Glycogen which stores glucose, and brain also lacks the 
anaerobic metabolism. The centers in the lower brain stem regulate the constant 
blood supply to the brain by stimulation of Vasomotor reflexes and 
Baroreceptors. Decrease in blood flow for even 4 to 10 minutes produces a 
rapid symptom of neurological deficit.22 
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The normal cerebral blood flow is 50-60 ml/100 gm/min.23 Below this 
level there is cerebral vasodilatation, the collaterals get opened and the oxygen 
extraction from the other cells increases. When it is less than 20ml/100gm/min, 
the cerebral auto regulatory mechanism gets impaired. The brain tissue goes for 
infarction over an hour, if the blood flow is 16-18ml/100gm/min. And finally 
irreversible neuronal injury occurs if blood flow is less than 10ml/100gm/min.24 
Once the infarction had occurred there is increased water accumulation 
immediately both intracellular and in intercellular spaces leading to swelling of 
the infarcted area. There is a release of inflammatory mediators and leucocyte 
gets recruited .These released mediators cause vasodilation and platelet 
aggregation. The immunoregulated platelets, erythrocytes and leukocytes gets 
adhered to the vessel wall leading to occlusion and ischemia. 
When brain tissue is completely deprived of the blood flow leading to 
irreversible neuronal destruction, it’s termed as Global Ischemia. If the 
collaterals are able to maintain the blood flow and oxygen it is known as focal 
ischemia. 
The core region surrounding infarcted area is ischemic. This zone is 
known as ischemic penumbra, which has viable neurons and marginal 
perfusion.25Maintaining the blood flow to this ischemic penumbra is the 
targeted factor in ischemic stroke because this ischemia area recovers from 
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injury once the flow is re-established but when the flow is not reversed it goes 
for infarction leading to worsening of the clinical status and outcome. Ischemic 
penumbra is seen in MRI / CT – perfusion- diffusion imaging. The newly 
emerging modalities of treatment like Revascularization therapies are aimed at 
saving the ischemic penumbra to prevent further infarction. 
There are two types of infarct 
 Pale Infarct 
 Hemorrhagic Infarct 
23 
 
 
PALE INFARCT 
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HEMORRHAGIC INFARCT 
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BIOCHEMICAL CHANGES: 
These depolarized cells when injured produce efflux of potassium, 
depletion of ATP and Creatine kinase. Groen et al proposed that low serum 
potassium increases the stroke rate26. Accumulation of free fatty acids destroys 
the phospholipids in cell membranes of neurons, which alters the calcium 
homeostasis. These changes lead to histological features of necrosis. The 
increased extracellular potassium and intracellular calcium causes cellular 
acidosis. 
The cells swell due to accumulation of cytokines and other inflammatory 
mediators like prostaglandins leading to cytotoxic edema.27 
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CHANGES DUE TO ALTERED METABOLIC FACTORS 
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GLUTAMATE: 
Glutamate is an excitatory neuron transmitter that is cleared by glutamate 
transporters from the extracellular space. Following stroke the glutamate 
transporters release glutamate. Glutamate is excitotoxic, so its release causes 
brain damage following stroke. Glutamate also increases calcium influx leading 
to persistent depolarization and activation of enzymes, release of cytokines and 
loss of cellular integrity. 
• Mitochondrial Dysfunction: 
Activation of neuronal NOS, inducible nitric oxide in glial cells lead to 
Mitochondrial damage and causes ischemia of the brain. 
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TYPES OF ISCHEMIC STROKE : 
 Acute stroke is classified by various classification systems, 
The Oxford Community Stroke Project classification (OCSP, also known 
as the Bamford or Oxford classification) relies primarily on the initial 
symptoms; based on the extent of the symptoms, the stroke episode is classified 
as- 
a) Total anterior circulation infarct (TACI). 
b) Partial anterior circulation infarct (PACI). 
c) Lacunar infarct (LACI). 
d) Posterior circulation infarct (POCI). 
 These four entities predict the extent of the stroke, the part of the brain 
affected the underlying cause, and the prognosis. 
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CIRCLE OF WILLIS 
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ANTERIOR CIRCULATION STROKE (ACS): 
 The major blood vessels involved in ACS are 
 Carotid Artery mainly internal carotid artery (ICA) 
 Middle cerebral artery (MCA) 
 Anterior cerebral artery 
 Anterior choroidal artery 
 When ACA and MCA are occluded at the top of carotid artery – abulia or 
stupor / occur with aphasia, anasognosia, hemiplegia, hemianisocoria and 
amaurosis fugax. 
Middle Cerebral Artery (MCA): 
MCA involvement causes symptoms of contralateral hemiplegia, 
homonymous hemianopia, hemianaesthesia, gaze preference to same side and 
Wernicke’s aphasia. 
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Anterior cerebral artery (ACA):  
ACA involvement causes bilateral pyramidal signs, profound abulia, 
paraparesis or quadriparesis and urinary incontinence.  
Anterior choroidal artery: 
Anterior choroidal artery involvement leads to contralateral hemiplegia, 
homonymous hemianopia and hemianaesthesia. 
Common carotid artery:  
Common carotid artery involvement causes Jaw claudication. 
POSTERIOR CIRCULATION STROKE (PCS): 
The arteries involved are posterior cerebral artery, posterior inferior 
cerebellar artery, Vertebral Artery, Basilar Artery. Posterior circulation 
syndromes are because of emboli / atheroma formation, at the top of basilar 
artery. P1 Syndrome and P2 Syndrome are due to posterior cerebral artery 
occlusion. 
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BLOOD SUPPLY TO BRAIN 
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The features are 
 Contralateral homonymous hemianopia with macular sparing. 
 Bilateral infarction of distal PCA  
 Cortical blindness 
 Anton’s Syndrome 
 Balint’s syndrome - Balint’s syndrome occurs due to infarction in water 
shed area between MCA and PCA. 
 Embolic occlusion of top of basilar artery - Bilateral signs, ptosis, 
pupillary asymmetry, absence of light reflex and somnolence. 
 Vertebral and Posterior ICA - Lateral medullary Syndrome,  
 Medial medullary Syndrome. 
 Hemiparesis is not the feature of vertebral artery occlusion, but 
quadriparesis can result from occlusion of anterior spinal artery. 
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INVESTIGATIONS: 
CT Brain: 
Brain CT scans obtained in the first several hours after an infarction 
generally show no abnormality, and the infarct may not be seen reliably for 24–
48 hours. 
MRI: 
MRI reliably documents the extent and location of infarction in all areas 
of the brain, including the posterior fossa and cortical surface. 
Conventional x-ray cerebral angiography: 
Conventional x-ray cerebral angiography is the gold standard for 
identifying and quantifying atherosclerotic stenosis of the cerebral arteries. 
Ultrasound Techniques: 
Stenosis at the origin of the internal carotid artery can be identified and 
quantified reliably by ultrasonography that combines a B-mode ultrasound 
image with a Doppler ultrasound assessment of flow velocity ("duplex" 
ultrasound). Transcranial Doppler (TCD) assessment of MCA, ACA, and PCA 
flow and of vertebrobasilar flow is also useful. This latter technique can detect 
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stenotic lesions in the large intracranial arteries because such lesions increase 
systolic flow velocity. Furthermore, TCD can assist thrombolysis and improve 
large artery recanalization following rtPA administration. 
Perfusion Techniques: 
Both xenon techniques (principally xenon-CT) and PET can quantify 
cerebral blood flow. These tools are generally used for research but can be 
useful for determining the significance of arterial stenosis and planning for 
revascularization surgery. Single-photon emission computed tomography 
(SPECT) and MR perfusion techniques report relative cerebral blood flow. 
Disability adjusted life year (DALY): 
Disability adjusted life year is used to measure the global burden of 
disease. It’s the healthy time lost by the patient due to early mortality and life 
with morbidity. Scandinavian stroke scale is commonly used in India to 
evaluate DALY.28 
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It is one of the commonly used clinical outcome measures in patients with 
stroke 
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Diabetes mellitus: 
Diabetic patients have 2 to 3 times greater risk of stroke than non-diabetic 
population according to Framingham survey .28 .and a number of other surveys 
too  proved this greater risk.  
ICMR study also suggested that uncontrolled hyperglycemia as an 
important risk factor for CVD. 
Dyslipidemia:  
 Serum lipid abnormities is associated with increased risk of stroke and 
carotid atherosclerosis. 4s trial, WOSCOPS &CARE study all show an 
association between serum lipids and increased stroke risk. 
Diabetic dyslipidemia:  
In type 2 diabetes and insulin resistance the dyslipidemia pattern is as follows    
 HDL – (decreased) – increased Clarence of Apo A 
                                     Decreased proportion of large HDL 
                                    Triglyceride enrichment  
                                    Diminished reveres cholesterol transport  
LDL – (qualitative abnormalities) – increased production Apo B 
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                                    Decreased Receptor mediated clearance 
                                    Smaller (more  denser) particle distribution  
VLDL –( increased) – increased production of triglyceride and Apo B  
                                    Decreased clearance of triglyceride and Apo  
Triglyceride - (increased)  
Lipoprotein (a)  Lp (a) – (increased) 
 
THE STRUCTURE OF LP(a): 
 Lipoprotein (a) is a molecule that resembles LDL. It is made of Apo 
B100 and Apo (a) linked by a disulfide bridge. Plasminogen, macrophage 
stimulating factor, tissue plasminogen activator, prothrombin and factor XII are 
a group of kringle containing proteins and Apo (a) is a member of it.  The 
sequence of LP (a) is much identical to that of plasminogen. Nearly 34 different 
alleles have been identified for the highly polymorphic Apo (a) gene. 
Corresponding isoforms with molecular weights ranging from 187 to 648 kDa 
were identified in human serum. The number of kringle IV type 2 repeats 
determine the size polymorphism of Apo (a).29 
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LIPOPROTEIN  (A)  STRUCTURE 
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Function 
The physiological function of  Lp (a)/Apo(a) is still 
unknown. Plasminogen gene duplication derives LPA gene leads to homologues 
between Apo (a) and plasminogen leads to possible function within coagulation 
system 
Other functions are helping in angiogenesis and wound healing by 
recruitment of inflammatory cells by interaction with Mac1 integrin. 
In GULO (l- gulonolactone oxidase)deficiency, lipoprotein a used as 
vitamin  c for arterial wall repair  by a poorly understandable mechanism  
 
Pathology 
  Lp (a) is structurally similar to plasminogen and tPA.  
 It competes with plasminogen during resolution of blood clot. 
 It reduces fibrinolysis and forms a hypercoaguable state leading to 
thrombogenesis as it secretes PAI-1. 
 It helps in atherosclerosis by being a carrier of cholesterol. 
 It causes recruitment of proinflammatory cells. 
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 Thus it causes inflammation and smooth muscle proliferation in vessel 
wall. 
Lipoprotein (a) and disease 
 High Lp (a) in blood is a risk factor for  
 Coronary heart disease (CHD), 
  Cerebrovascular disease (CVD), 

  Atherosclerosis,  Thrombosis.  
 Lp(a)  concentrations may be affected by disease states, (for example 
renal failure), but are only slightly affected by diet, exercise, and other 
environmental factors. 
 High Lp (a) predicts risk of early atherosclerosis independent of other 
cardiac risk factors, including LDL.  
 Lp (a) indicates a coagulant risk of plaque thrombosis.  
Diagnostic testing 
The European Atherosclerosis Society recommends that patients with a 
moderate or high risk of atherosclerosis and cardio and cerebrovascular events 
have their lipoprotein (a) levels checked.  Patients with following risk factors 
must be screened 
 premature cardiovascular disease 
 familial hypercholesterolemia 
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 family history of elevated lipoprotein (a) 
 recurrent cardiovascular disease  
If the level is elevated, treatment should be initiated and the goal will be of 
bringing the level below 50 mg/dl 
The Atherosclerosis Risk in Communities (ARIC) followed 3467 African 
Americans and 9851 whites for 20 years. The research shows that an elevated 
Lp (a) has the same risk in each group. However, African Americans had 
roughly three times the level of Lp (a), and Lp(a) also predicted an increased 
risk of stroke.32  
 A standardized international reference material has been developed and is 
accepted by the WHO Expert Committee on Biological Standardization and the 
International Federation of Clinical Chemistry and Laboratory Medicine.  
 Lipoprotein (a) – Lp (a) level [37] 
 Desirable: < 14 mg/dl (< 35 nmol/l) 
 Borderline risk: 14 - 30 mg/dl (35 - 75 nmol/l) 
 High risk: 31 - 50 mg/dl (75 - 125 nmol/l)  
 Very high risk: > 50 mg/dl (> 125 nmol/l) 
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LIPOPROTEIN(A), DIABETES AND ISCHEMIC STROKE : 
           Dyslipidemia, lipoprotein(a) and diabetes are risk factors for ischemic 
stroke . Lipoprotein (a) has atherogenic and thrombotic properties. This 
potential of lipoprotein (a) could be increased in diabetic patients. 
Atherogenicity of lipoprotein ( a) at molecular and cellular level is caused by  
 Interference with fibrinolytic system,  
 Affinity to secretory phospholipase A2,  
 Interaction with extracellular matrix glycoprotein and 
 Binding scavenger receptor on macrophage.  
Little evidence in previous studies shows that there is correlation between 
increased risk of atherogenicity and lipoprotein( a )among diabetic patients. 
          Lipoprotein a  is an important factor that links micro vascular and macro 
vascular complications of diabetes. 
       In previous studies contribution of lipoprotein (a) to enhanced risk of 
vascular disease in diabetes mellitus population is not clearly defined. 
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     Lipoprotein a can promote thrombosis, inflammation, and foam cell 
formation. 
          EPK study already clearly discussed that lipoprotein (a) and risk of CAD 
and stroke is well established and also added  
Lipoprotein (a) associated with Peripheral arterial disease, Coronary 
artery disease and ischemic stroke. 
 All these previous studies clearly shows high lipoprotein ( a) is an 
independent risk factor for the development of cerebral infarction . 
 Lp (a) must measure by uniform methods in future and its involvement 
in pathogenesis of stroke sub types is still unsettled. 
This study is to evaluate the lipoprotein (a) level as an early marker to 
assess the severity of ischemic stroke in Type II diabetic patients 
Whether lipoprotein (a) can act as an early marker (or) early predictor for 
worse prognosis in diabetic patients with ischemic stroke when compared to 
non-diabetics was unclear. Studies have also shown that high lipoprotein (a) 
predicts risk of early atherosclerosis independently of other stroke risk factors 
including LDL cholesterol. 
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LIPID VARIABLES AND THE RISK OF STROKE 
 
TOTAL CHOLESTEROL AND STROKE; 
 
 Total cholesterol level is a risk factor for stroke, TIA and ischemic heart 
diseases .The raise in total cholesterol is directly proportional to IHD but not to 
stroke as different blood vessel with different pressure gradients are involved.  
Only highest level of TC directly increases non-hemorrhagic stroke not the 
intermediate level cholesterol .30 
 
 
HDL CHOLESTEROL AND STROKE 
 
 Majority of the studies shows an inverse relationship between HDL level 
and risk of stroke  
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Lipoprotein (a) and atherosclerosis 
Following studies done in the past supports lipoprotein (a) association 
with stroke/atherosclerosis 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Jurgens and Koltringer (1987) -31 
 Lindgren et al (1992)- 32  
 Vavernova et al (1993)33 
 Jurgens et al (1995)34 
 Peynet et al (1999)35 
 Van Kooten et al (1996)36 
 Margaglione et al (1996)37 
 Nagayama et al (1994)38 
 Peng et al (1999)39 
 Kario et al (1996)40 
 ARIC study* (1994)41 
 Ichinose et al (1998)42 
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 All these following studies are supporting the role of lipoprotein (a) with 
stroke and atherosclerosis association.  
Lipid profile of 131 stroke patients studied by Lindgren et el 6 month 
later showed elevated LP (a) and TG levels and decreased LDL HDL TC level 
than the controls. 
  Van Kooten’s  study on stroke patients showed significantly raised 
Lp(a) values but stroke characteristics prognosis and CVD risk profile has got 
no association with Lp(a)  level.43 
Lipoprotein A in acute ischemic stroke; In the atherosclerosis risk in 
communities (ARIC) study, 
  In this study conducted on 15160 stroke patients showed Lp (a) as risk 
factor for stroke and TIA in all races (blacks and whites) but stroke morbidity 
does not show any racial difference. Lp(a) concentration is directly 
proportionate to the incidence of ischemic stroke . 
 Pedro-Bodet et al, studied Apo E 4 gene in ischemic stroke patients in a 
case control study. It showed that in ischemic stroke patients there is a higher 
frequency of Apo E4 gene. 45 
 Apo (a) modulates smooth muscle cell proliferation, enhances lipid 
deposition in vessel wall, and inhibits fibrinolysis and thus causing endothelial 
dysfunction. 
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Watts and his colleagues observed the lipid profile in those with TIA. 
They showed a significant association between Lp (a)   concentration and the 
extent of carotid atherosclerosis. 47 
 
Lp(A) and diabetes:  
A cluster of interrelated plasma lipid and lipoprotein abnormalities 
associated with alterations in VLDL metabolism contribute to the risk for 
atherosclerosis and CHD in the majority of patients with type 2 diabetes. Insulin 
resistance plays a key role in the development of diabetic dyslipidemia. Each of 
the lipid abnormalities (low HDL, small dense LDL, and elevated triglycerides) 
is associated with an increased risk of CHD48 
 
Diagram showing various pathways linked with dyslipidemia and in 
diabetics 
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Hypothetical scheme for the relation of altered metabolism of 
triglyceride-rich lipoproteins to the development of an atherogenic lipoprotein 
phenotype.  
CETP-cholesterol ester transfer protein; Chol- cholesterol;     
HL-hepatic lipase; LDLR-LDL receptor; LPL- lipoprotein lipase; TG-
triglyceride. 
Each of the lipid abnormalities (low HDL, small dense LDL, and elevated 
triglycerides) is associated with an increased risk of CHD. 
Our aim is to to compare lipoprotein (a) level in Type II diabetic and non-
diabetic patient with ischemic stroke 
 
  
 
 
 
METHODOLOGY 
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METHODOLOGY 
Title 
LIPOPROTEIN (a) IN ISCHEMIC STROKE- A 
COMPARATIVE STUDY BETWEEN TYPE II 
DIABETIC VS NON DIABETIC PATIENTS   
Aims and Objectives 
 
Primary Objectives (s) 
 
 
Secondary Objective(s) 
 
 
To compare lipoprotein (a) level in Type II diabetic 
and non-diabetic patients with ischemic stroke 
 
To evaluate lipoprotein (a) level as an early marker to 
assess severity of ischemic stroke in Type II diabetic 
patients 
Study Centre 
Institute of Internal Medicine, Madras Medical 
College and Rajiv Gandhi Government General 
Hospital, Chennai 
Duration of the Study 6 months 
Study Design Cross sectional study 
Sample Size 100 patients 
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Inclusion Criteria 
Patients of stroke diagnosed clinically and proven 
radio-logically 
Age above 40 years 
Exclusion Criteria 
Patients with hemorrhagic stroke 
Patients with cardio-embolic stroke 
Patient with liver disease 
Patient with smoking and alcoholic 
Patient taking antilipidemic drugs 
Data Collection and 
Methods 
Patients have their history taken according to a 
Questionnaire and subjected to clinical examination 
Methodology 
(Materials and 
Methods) 
Study was conducted in 100 patients of ischemic 
stroke(CT proven) 
Subject were divided into two groups 
Group 1 - 50 patients with type II diabetes 
Group 2 - 50 patients with non-diabetes 
Patient are subjected to routine blood investigations 
CBC,RFT,LFT  and  fasting lipid profile, 
lipoprotein(a),fasting blood sugar ,HbA1c,  CT brain 
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Patients are followed for at least four weeks or until 
death if earlier and their lipoprotein (a) level in 
ischemic stroke with type II diabetic and non-diabetic 
are compared 
Product / Procedure / 
Investigation Details 
CT brain, lipid profile, lipoprotein (a) 
Analysis Plan SPSS, Epi INFO 
Sponsorship (Yes/ No) 
If Yes details 
No 
Conflict of Interest No 
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Table 1: 
RESULTS AND OBSERVATION : 
 
 
Type II DIABETIC 
 
NON DIABETIC 
   
Count Table % Count Table % 
sex MALE 32 32.0% 30 30.0% 
   
FEMALE 
18 18.0% 20 20.0% 
Smoker  YES 25 25.0% 26 26.0% 
   
NO 
25 25.0% 24 24.0% 
alcoholic YES 20 20.0% 14 14.0% 
   
NO 
30 30.0% 36 36.0% 
MORIBIDITY <15 23 23.0% 15 15.0% 
   
>15 
27 27.0% 35 35.0% 
 
 
Variables for 100 ischemic stroke patients were divided according to their 
age , gender, smoking ,alcoholic, and their morbidity were  compared between 
both type II diabetic and non-diabetic . 
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Table 2: 
 
P value for Diabetic patients 
 
AGE GROUP * lipo protein  (a )  value 
 
 
  
 
  
lipoprotein(a) value Total 
   
15 – 30 
30 - 50 
 
   
Count 
%  Count %  Count %  
AGE 
GROUP 
40- 50 8 47.1% 6 18.2% 14 28.0% 
   
50 -60 7 41.2% 11 33.3% 18 36.0% 
   
60 -70  2 11.8% 13 39.4% 15 30.0% 
   
above 
70 
0 .0% 3 9.1% 3 6.0% 
Total 17 100.0% 33 100.0% 50 100.0% 
P value :0.05 Significant 
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 Descriptive Statistics 
 
  N 
Minim
um 
Maxim
um Mean 
Std. 
Deviation 
AGE 50 42 73 57.06 8.153 
Valid N 
(listwise) 50         
 
 
In our study patients with age above 40years were studied. The minimum 
age  was 42  and maximum age was 73   and mean age was 57.06 .   
As age increases the risk of stroke also increases (p value  0.05)  
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42 Table 3 
 
sex * lipo protein (a) value 
 
 
  
lipo protein value Total 
   
15 – 30 
30 - 50 
   
Count 
%  Count %  Count %  
sex   
   
Male 9 52.9 23 69.7 32 64.0 
sex Female 8 47.1 10 30.3 18 36.0 
Total 17 100 33 100 50 100 
 
P value :0.242 Not Significant 
 
 
 
In our study there is no gender difference in lipoprotein (a) value 
( p value  0.242)   
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Chart 1: 
Percentage distribution of gender  among ischemic stroke patients 
compared between diabetic and non diabetic . 
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Table 4: 
 
 
Smoker  * lipo protein (a) value 
 
   
lipo protein value Total 
   
15 – 30 
30 - 50 
   
Count 
%  Count %  Count %  
Smoker Yes 8 47.1% 17 51.5% 25 50.0% 
Smoker No 9 52.9% 16 48.5% 25 50.0% 
Total 17 100.0% 33 100.0% 50 100.0% 
P value :0.765 Not Significant 
 
 
 
In our study there is no relationship between smoker and lipoprotein (a) 
level as indicated by p value 0.765  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60 
 
 
Chart:2 
 
Percentage distribution of smoking among ischemic stroke patients 
compared between diabetic and non diabetic . 
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Table 5: 
 
alcoholic * lipo protein (a) value 
 
 
    
lipo protein value Total 
   
15 – 30 
30 - 50 
   
Count 
%  Count %  Count %  
alcoholic YES 7 41.2% 13 39.4% 20 40.0% 
   
NO 10 58.8% 20 60.6% 30 60.0% 
Total 17 100.0% 33 100.0% 50 100.0% 
P value :0.903 Not Significant 
   
 
From our study  there is no significant difference in lipoprotein (a) level 
between alcoholic and non alcoholic  p value 0.903  
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Chart 3: 
 
Distribution of alcoholic and non alcoholic ischemic stroke patients 
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Chart 4: 
Fasting blood sugar level in type 2 diabetic and non diabetic patients 
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Chart 5: 
HbA1c level in type II diabetic and non- diabetic ischemic stroke patient. 
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Table 6 : 
Lipoprotein (a) levels in Type II diabetic and non-diabetic patients  with 
ischemic stroke 
 
 
 
Total Type II DIABETIC NON DIABETIC 
Lp a value1 <14 0 0 0 
 15 - 30 17 27 44 
 30 - 50 33 23 56 
>50 0 0 0 
Total 50 50 100 
 
 Value df P value 
Pearson Chi-Square 4.058(b) 1 .044 
 
The association between lipoprotein (a) value and ischemic stroke is 
significant (p value 0.044) 
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Table 7: 
Comparison of lipoprotein( a ) level in both type II diabetic and non-
diabetic  patients. 
 
Independent Samples Test 
t-test for Equality of Means 
t df P value 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
         Lower Upper 
       
2.011* 96.954 0.047 3.84 1.910 .049 7.631 
 
There is a significant  difference in lipoprotein (a) level between  type II 
diabetic and non-diabetic  ischemic  stroke patients(  p value 0.047)  
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Chart 8: 
 
Lipoprotein (a) level distribution in type II diabetic and non-diabetic 
ischemic stroke patients 
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Table 9: 
Evaluation  of lipoprotein (a) level as  a marker to assess severity of 
ischemic stroke in Type II diabetic and non-diabetic  
patients using Scandinavian score 
 
    Total  
    
TYPE II 
DIABETI
C 
NON 
DIABETI
C   
 
MORIBIDITY <15 Count 23 15 38  
    % within 
MORIBIDITY 
60.5% 39.5% 
100.0
% 
P= 0.099 
Not 
significa
nt  
P>0.05 
  >15 Count 27 35 62  
    % within 
MORIBIDITY 
43.5% 56.5% 
100.0
% 
 
Total Count 50 50 100  
  % within 
MORIBIDITY 50.0% 50.0% 
100.0
% 
 
 
Lipoprotein (a) value cannot be used to assess severity of ischemic stroke 
as our p value 0.099 using Scandinavian score. 
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Table 10: 
Scandinavian score distribution 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 2 6 6.0 6.0 6.0 
   
4 
6 6.0 6.0 12.0 
   
6 
7 7.0 7.0 19.0 
   
8 
6 6.0 6.0 25.0 
   
10 
4 4.0 4.0 29.0 
   
12 
6 6.0 6.0 35.0 
   
14 
7 7.0 7.0 42.0 
   
16 
19 19.0 19.0 61.0 
   
18 
28 28.0 28.0 89.0 
   
20 
11 11.0 11.0 100.0 
   
Total 
100 100.0 100.0   
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Chart 9: 
Scandinavian score distribution in 100 ischemic stroke patients 
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Chart 10: 
 
Scandinavian sore in 100 ischemic stroke patients to assess severity in type 
2 diabetes and non diabetes 
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Table 11: 
 
Lipid profile in type 2 diabetic and non diabetic ischemic stroke patients 
 
 
Mean 
Media
n 
Std.De
viation 
Mean Median 
Std.Deviatio
n 
LDL 164.1 162.5 40 97.7 96 35 
HDL 34 36 7 41 40 7 
TC 235 224 38 203 211 26 
TG 251 240 50 152.2 115 60 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
 
Chart 11: 
Serum HDL level in type II diabetic and non diabetic ischemic  
stroke patients 
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Chart 13: 
 
LDL and Triglyceride level in type 2 diabetic and non diabetic  
ischemic stroke patient. 
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DISCUSSION 
                 
This study was a cross sectional study conducted in 100 Ischemic stroke 
patients admitted in Rajiv Gandhi government general hospital. These patients 
were divided into two groups 50 each. Group-1 includes Type II diabetes with 
ischemic   stroke and Group-2 includes non-diabetics with ischemic stroke. 
 
62 were males and 38 were females. Age of the study group was more 
than 40 years.Mean age of study group 57.06.  
 
The results from this study showed Lipoprotein (a) level to be 
significantly elevated in ischemic stroke patients who had diabetes, than who 
were non diabetic.P value 0.044. 
 
This study also showed that patients with elevated Lipoprotein (a)  levels 
had no significant  difference in morbidity and mortality  between diabetic and  
non-diabetic patients which shows - p value -  0.099  (p more than 0.05  ) 
 
In stroke and TIA  Lp (a) is observed to be an independent risk factor in 
ARIC study. 
 
Zenker et al study showed  that  Lipoprotein (a)  is not only a risk factor 
for CAD but also for CVD.( p value less than 0.01) 
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Decreased HDL, increased LP (a) ,IDL ,LDL ,TC are seen in patients 
with ischemic stroke in the study conducted by pedreno j et el Similar results 
have been concluded in our study which showed decreased HDL  in diabetic 
patients with ischemic stroke. 
 
Naoki nago et al study conducted in Japanese population with 1235 males 
and 1762 females over 30 years old found mean Lipoprotein (a) level were 
higher in females than males. Not much study has been conducted in Indian 
population. 
 
The same study also concluded that LP(a) level is inversely proportional 
with alcoholics and also with TGL levels. 
 
Increased concentration of TG, Lp (a) and decreased con centration of 
HDL, TC and LDL pattern of lipoid profile is observed in ischemic stroke in  
Lindgren et el’s study In our study also patient with ischemic stroke has higher 
lipoprotein (a) , triglyceride level and lower HDL  levels. Total cholesterol and 
serum LDL levels do not show significant abnormal values.   
        
         Nagayama et al’ studied that Lpa levels were higher in patients with 
ischemic stroke of less than 70 years. Study conducted by Maurizio  
margaglione et al ‘ also showed that LP(a) level is higher in patients less than 
70 years with ischemic stroke.In our study patients aged more than 40 years 
were studied and was found to have elevated lipoprotein (a) levels. 
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Maurus marques et al’ conducted study in 60 patients with ischemic 
stroke and when compared between diabetics and non-diabetics mean 
Lipoprotein (a) level was high in diabetics than non-diabetics. I n our study also 
the mean lipoprotein (a) level was higher in diabetics than non-diabetics -  p 
value in our study 0.047 (p value less than 0.05) 
 
Jenkin’ s et al study concluded that vascular complications like ischemic 
stroke and myocardial infarction are higher in patients with  elevated lipoprotein 
(a ) level in our study p value 0.044 (p value less than 0.05) significant 
association between increasing lipoprotein a level and ischemic stroke . But our 
study being a retrospective study in ischemic stroke patients with diabetes 
having significant elevation of lipoprotein (a ) level would also serve to suggest 
that lipoprotein (a) as an independent risk factor to  develop ischemic stroke. 
Further prospective studies could be done to evaluate this. 
 
 
 
 
 
 
 
 
  
 
 
LIMITATIONS OF THIS STUDY 
  
78 
 
 
LIMITATIONS OF STUDY 
 
1. Study sample was small only 100 patients with ischemic stroke 50 
patients with type 2 diabetic and 50 patients with non-diabetic.  
 
2. Long term follow up of the patients was difficult, so the follow up 
study was done for a short duration of   7 days. If the patients were followed up 
for 6 months as done in other studies, the correlation of lipoprotein a with 
ischemic stroke   with    Scandinavian score Scale would be much more ideal. 
 
3.  The controls were matched only for age and sex and not for other risk 
factors which would have been ideal. 
 
4. Seriously ill patients admitted in intensive care units were not included 
in this study due to difficulty in getting the consent. This might have lead to 
selection bias. 
 
5. People admitted during our study period only compared, if more 
patients and if studies conducted for long period then it may be more ideal as 
other studies are done. 
 
  
 
 
CONCLUSION 
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CONCLUSION 
 
 In our study, a significant association of lipoprotein (a) concentration 
with ischemic stroke  was inferred- p value -0.044  
 
 Increased levels of lipoprotein(a) in type II diabetic patients was found to 
have increased predilection to ischemic stroke when compared to non 
diabetics .( P value -0.047) 
 
 Although  study showed increased predilection of lipoprotein (a) in 
ischemic stroke, Lipoprotein (a) levels  skewed  towards higher values in 
both type 2 diabetic and non-diabetics. 
 
 In our study conducted  in 100 ischemic patients, 50  diabetic patients 
were compared  with non diabetics and was followed  up  for 7 days or 
until death whichever is earlier .The significance inferred was- p value 
0.099. So from our study lipoprotein (a) cannot be used as a surrogate 
marker to assess severity of ischemic stroke. 
 
 
 
  
 
 
BIBLIOGRAPHY 
  
80 
 
 
 
BIBLIOGRAPHY 
1. The history of stroke and cerebrovascular disease,MaurizioPaciaroni, 
JulienBogousslavsky, Stroke Unit and Division of Cardiovascular Medicine, 
University of Perugia, Santa Maria dellaMisericordia Hospital, Perugia, Italy 
Department of Neurology and Neurorehabilitation, Genolier Swiss Medical 
Network, 1823, Glion/Montreux, Switzerland. 
2. Thompson JE (August 1, 1996). "The evolution of surgery for the treatment 
and prevention of stroke. The Willis Lecture". Stroke 27 (8):  
1427–34.  
3. Kopito, Jeff (September 2001). "A Stroke in Time". MERGINET.com 
4. R. Barnhart, ed. The Barnhart Concise Dictionary of Etymology (1995)  
5. Schiller F (April 1970). "Concepts of stroke before and after Virchow". 
Med Hist14 (2): 
6 .2013;992:407-12. doi: 10.1007/978-1-62703-339-8_33. 
Testing for apolipoprotein(a) phenotype using isoelectric focusing and 
immunoblotting technique.  
 
81 
 
7.Global and regional burden of stroke during 1990—2010: findings from the 
Global Burden of Disease Study 2010.The Lancet, Early Online Publication, 24 
October 2013.doi:10.1016/S0140-6736(13)61953-4 
8.Thompson JE (August 1, 1996). "The evolution of surgery for the treatment 
and prevention of stroke.The Willis Lecture". Stroke 27 (8): 1427–
34.doi:10.1161/01.STR.27.8.1427. PMID 8711815 
9. .Thompson JE (August 1, 1996).  "The evolution of surgery for the treatment 
and prevention of stroke.The Willis Lecture". Stroke 27 (8): 1427–
34.doi:10.1161/01.STR.27.8.1427. PMID 8711815, National Institute of 
Neurological Disorders and Stroke (NINDS) (1999). "Stroke: Hope Through 
Research". National Institutes of Health. 
10. Easton JD et al: Definition and evaluation of transient ischemic attack. 
Stroke 40: 2276, 2009[PMID: 19423857]   
11.Ames A, Nesbett FB: Pathophysiology of ischemic cell death: I. Time of 
onset of irreversible damage: Importance of the different components of the 
ischemic insult. Stroke 14:219, 1983. [PMID: 6836647]  
12. Ames A, Nesbett FB: Pathophysiology of ischemic cell death: III. Role of 
extracellular factors.Stroke 14:233, 1983. [PMID: 6836649] 
82 
 
13. Ames A, Nesbett FB: Pathophysiology of ischemic cell death: II. Changes 
in plasma membrane permeability and cell volume.Stroke 14:227, 1983. 
[PMID: 6836648]  
14.Ames A, Wright RL, Kowada M, et al: Cerebral ischemia: II. The no-reflow 
phenomenon.Am J Pathol 52:437, 1968. [PMID: 5635861] 
15.Hossman K-A: Pathophysiology of cerebral infarction, in Vinken PJ, Bruyn 
GW, Klawans HL (eds): Handbook of Clinical Neurology. Vol 53.Vascular 
Diseases. Part I. Amsterdam, Elsevier, 1988, pp 27–46. 
16.Ross R. Cell biology of atherosclerosis. Annual Review of Physiology 1995; 
57:791-804 . ) 
17.Smith WS, English JD, Johnson SC. Cerebrovascular diseases. Harrison‘s 
Principles of Internal Medicine. Ed.FauciAS,BraunwaldE,Kasper DL, Hauser 
SL, Longo DL, Jameson JL et al 17th ed.McGraw Hill ; Volume 2;2513-2535. 
18. Victor M, Ropper AH, Adams RD.Cerebrovasculardiseases.Adam‘s and 
Victor‘s Principles of Neurology.Ed.Ropper A H,Samuels MA. 9th ed. United 
States of America,McGraw Hill 2009 
19.Cordonnier C, Leys D. Stroke, the bare essentials. Neurology in Practice 
2008;8:263–272. 
20. PK Sethi. Stroke - Incidence in India and management of ischaemic stroke. 
Neurosciences Today; Vol VI no 3. July -September. 2002. 
83 
 
21.Greisenegger S, Endler G, Hsieh K, Tentschert S, Donnan GA, Fisher M, 
Macleod M, Davis SM (May 2008). "Stroke".Lancet371 (9624): 1612. 
22.Bamford J, Sandercock P, Dennis M, Burn J, Warlow C (June 1991). 
"Classification and natural history of clinically identifiable subtypes of cerebral 
infarction".Lancet337 (8756): 1521–6. 
23.Bamford JM (2000). "The role of the clinical examination in the 
subclassification of stroke".Cerebrovascular Diseases10 Suppl 4: 2–4. 
24. Adams HP, Bendixen BH, Kappelle LJ et al. (January 1993). "Classification 
of subtype of acute ischemic stroke.Definitions for use in a multicenter clinical 
trial.TOAST.Trial of Org 10172 in Acute Stroke Treatment".Stroke24 (1):  
35–41. 
25.Caplan LR: "Top of the basilar" syndrome. Neurology 30:72, 1980. [PMID: 
7188637] 
26.Bonita R, Beaglehole R. ―Modification of Rankin Scale: Recovery of motor 
function after stroke.‖ Stroke 1988 ; 19(12):1497-1500. 
27.Smith N, Pathansali R, Bath P. Platelets and stroke. Vascular medicine 1999; 
4:165-172. 
28.BMC Neurology 2008, 8:12  doi:10.1186/1471-2377-8-12BMC 
Neurology 2008, 8:12  doi:10.1186/1471-2377-8-12 
29. lipoprotein and atherosclerosis http://jcp.bmj.com/external-
ref?access_num=A1994PD60100001&link_type 
84 
 
30.Acobs DR. The relationship between cholesterol and stroke. Health Rep 
1994;6:87–93. [Medline] Jurgens G, Koltringer P. Lipoprotein (a) in ischemic 
cerebrovascular disease: a new approach to the assessment of risk for 
stroke. Neurology 1987;37:513–15. 
31. Lindgren A, Nilsson-Ehle P, Norrving B, et al. Plasma lipids and 
lipoproteins in subtypes of stroke. Acta Neurol Scand 1992;86:572–8 
32 .Vavernova H, Novotny D, Ficker L, et al. Lipoprotein (a): a genetic risk 
factor for early ischemic cerebrovascular stroke. Vnitr Lek 1993;39:979–87. 
 33. Jurgens G, Taddei-Peters WC, Koltringer P, et al. Lipoprotein (a) serum 
concentration and apolipoprotein (a) phenotype correlate with severity and 
presence of ischemic cerebrovascular disease. Stroke 1995;26:1841–8. 
 34 . Peynet J, Beaudeux JL, Woimant F, et al. Apolipoprotein (a) size 
polymorphism in young adults with ischemic stroke.  
Atherosclerosis 1999;142:233–9. 
 35. . Van Kooten F, van Krimpen J, Dippel DW, et al. Lipoprotein (a) in 
patients with acute cerebral ischemia. Stroke 1996;27:1231–5. 
 36. Margaglione M, DiMinno G, Grandone E, et al. Plasma lipoprotein (a) in 
subjects attending a metabolic ward. Discriminations between individuals with 
85 
 
and without a history of ischemic stroke. Arterioscl Thromb Vasc 
Biol 1996;16:120–8. 
37. Nagayama M, Shinohara Y, Nagayama T. Lipoprotein (a) and ischemic 
cerebrovascular disease in young adults. Stroke 1994;25:748. 
 38. Peng D-Q, Zhao SP, Wang JL. Lipoprotein (a) and apolipoprotein E e4 as 
independent risk factors in ischemic stroke. J Cardiovasc Risk 1999;6:1–6. 
 39. National Institute of Neurological Disorders and Stroke Ad Hoc Committee 
(Whisnant JP, Basford JR, Bernstein EF, et al). Classification of 
cerebrovascular disorders III. Stroke1990;21:637–76 
 40. Kawamoto, A, Shimada K, Matsubayashi K, et al. Factors associated with 
silent multiple lacunar lesions on magnetic resonance imaging in asymptomatic 
elderly hypertensive patients. Clin Exp Pharmacol Physiol 1991;18:605–10. 
 41. Kario K, Matsuo T, Kobayashi H, et al. “Silent” cerebral infarction is 
associated with hypercoagulability, endothelial cell damage, and high Lp(a) 
levels in elderly Japanese.Arterioscler Thromb Vasc Biol 1996;16:734–41. 
 42. Schreiner PJ, Chambless LE, Brown SA, et al. Lipoprotein (a) as a correlate 
of stroke and transient ischemic attack prevalence in a biracial cohort: the ARIC 
study. Atherosclerosis risk in communities. Ann Epidemiol 1994;4:351–9. 
  
86 
 
43. chinose A, Suzuki K, Saito T. Apolipoprotein (a) and thrombosis: molecular 
and genetic bases of hyper-lipoprotein (a)-emia. Semin Thromb 
Hemost 1998;24:237–43. 
 44. Van Kooten F, van Krimpen J, Dippel DW, et al. Lipoprotein (a) in patients 
with acute cerebral ischemia. Stroke 1996;27:1231–5. 
45. Schreiner PJ, Chambless LE, Brown SA, et al. Lipoprotein (a) as a correlate 
of stroke and transient ischemic attack prevalence in a biracial cohort: the ARIC 
study. Atherosclerosis risk in communities. Ann Epidemiol 1994;4:351–9. 
[Medline] 
46. Pedro-Bodet J, Senti M, Nogues X, et al. Lipoprotein and apoprotein profile 
in men with ischemic stroke: role of lipoprotein (a), triglyceride-rich 
lipoproteins and apolipoprotein E polymorphism. Stroke 1992;23:1557–662. 
47. Watts GF, Mazurkiewicz JC, Tonge K, et al. Lipoprotein (a) as a 
determinant of the severity of angiographically defined carotid atherosclerosis. 
Q J Med 1995;88:321–6. 
48. Lipids and Lipoproteins in Patients With Type 2 Diabetes doi: 
10.2337/diacare.27.6.1496 
Diabetes Care June 2004 vol. 27 no. 6 1496-1504 
 
 
 
  
 
 
 
ANNEXURES 
 
87 
 
LIPOPROTEIN (a) IN ISCHEMIC STROKE - A COMPARATIVE 
STUDY BETWEEN TYPE II DIABETIC VS  
NON-DIABETIC  PATIENTS 
 
PROFORMA 
 
NAME OF THE PATIENT : 
AGE / SEX    : 
IP/OP NUMBER   : 
OCCUPATION   : 
ADDRESS    : 
 
CONTACT NUMBER  : 
COMPLAINTS   : 
 
PAST HISTORY   : 
TREATMENT HISTORY : 
DRUG ALLERGY  : 
GENERAL EXAMINATION : 
 
VITALS     : 
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SYSTEMIC EXAMINATION 
CARDIOVASCULAR SYSTEM : 
 
RESPIRATORY SYSTEM    : 
 
ABDOMEN            : 
 
CENTRAL NERVOUS SYSTEM :  Higher motor function  
                                                           Cranial nerves  
                                                           Motor system 
                                                           Sensory system  
                                                           Cerebellar signs 
INVESTIGATIONS    : 
CBC      : 
RFT- GLUCOSE    
         UREA 
         CRETININE 
         NA+ 
         K+ 
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LFT- Total bilirubin    : 
          Direct bilirubin 
          SGOT 
          SGPT 
         ALP 
         Total protein 
         Albumin 
Chest  x ray 
Echocardiography    : 
Ultrasound abdomen   : 
FASTING LIPID PROFILE  : 
LIPOPROTEIN (a)    : 
FASTING BLOOD SUGAR  : 
HbA1C     : 
CT BRAIN      :
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INFORMATION SHEET 
 
We are conducting a study on “LIPOPROTEIN (a) IN ISCHEMIC 
STROKE- A COMPARATIVE STUDY BETWEEN TYPE II DIABETIC 
VS NON DIABETIC PATIENTS” among patients attending Rajiv Gandhi 
Government General Hospital, Chennai and for that your specimen may be 
valuable to us. 
The purpose of this study to evaluate lipoprotein (a) level as early marker 
to assess severity of ischemic stroke in diabetic patient 
We are selecting certain cases and if you are found eligible, we may be 
using your specimen to perform extra tests and special studies which in any way 
do not affect your final report or management. 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid in 
the management or treatment. 
 
Signature of Investigator 
 
Signature of Participant 
 
Date: 
Place:  
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PATIENT CONSENT FORM 
 
Study Detail : LIPOPROTEIN (a) IN ISCHEMIC STROKE- A 
COMPARATIVE STUDY BETWEEN TYPE II 
DIABETIC VS NON DIABETIC PATIENTS   
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask questions and all my questions and 
doubts have been answered to my complete satisfaction. ❏ 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected. ❏ 
I understand that sponsors of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities 
will not need my permission to look at my health records, both in 
respect of current study and any further research that may be conducted 
in relation to it, even if I withdraw from the study I agree to this access. 
However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that 
arise from this study. ❏ 
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and ❏ 
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to immediately inform the study staff if I suffer from any deterioration 
in my health or well-being or any unexpected or unusual symptoms. 
I hereby consent to participate in this study. ❏ 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological tests. ❏ 
 
 
Signature/thumb impression 
Patient’s Name and Address:  
 
 
                                                                                                                                          
Signature of Investigator 
 
Study Investigator’s Name: 
Dr. R. RAVINDRAN 
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SL.NO AGE Sex SMOKER ALCOHOLIC Diabetic Status FBS 
mg/dl 
HBA1C 
% 
Lipo 
Protein 
(a) mg/dl 
MORBIDITY MORTALITY 
Scandi 
navian 
Score 
VAR 
1 48 MALE YES YES DIABETIC 132 8.1 16 16 ALIVE >15 15 - 30 
2 54 MALE NO YES DIABETIC 174 9.3 28 12 ALIVE <15 15 - 30 
3 51 MALE YES YES DIABETIC 144 7.3 20 10 ALIVE <15 15 - 30 
4 63 MALE YES NO DIABETIC 169 7.2 31 4 ALIVE <15 30 - 50 
5 66 FEMALE NO NO DIABETIC 134 9.7 31 2 DEATH <15 30 - 50 
6 57 MALE YES YES DIABETIC 164 7.8 31 8 ALIVE <15 30 - 50 
7 62 FEMALE NO NO DIABETIC 128 8.2 26 12 ALIVE <15 15 - 30 
8 49 MALE YES YES DIABETIC 167 9.1 15 4 ALIVE <15 15 - 30 
9 50 FEMALE NO NO DIABETIC 161 8.1 23 6 ALIVE <15 15 - 30 
10 55 FEMALE NO NO DIABETIC 170 7.7 18 14 ALIVE <15 15 - 30 
11 47 MALE YES NO DIABETIC 163 9.2 26 6 ALIVE <15 15 - 30 
12 60 FEMALE NO NO DIABETIC 175 7.3 24 2 ALIVE <15 15 - 30 
13 42 MALE YES YES DIABETIC 174 9.6 20 8 ALIVE <15 15 - 30 
14 61 MALE YES NO DIABETIC 136 7.9 32 16 ALIVE >15 30 - 50 
15 59 FEMALE NO NO DIABETIC 130 8.4 22 4 ALIVE <15 15 - 30 
16 44 MALE YES YES DIABETIC 133 8.9 15 6 ALIVE <15 15 - 30 
17 52 FEMALE NO NO DIABETIC 148 7.6 20 4 ALIVE <15 15 - 30 
18 64 FEMALE NO NO DIABETIC 168 7.7 16 12 ALIVE <15 15 - 30 
19 60 FEMALE NO NO DIABETIC 168 10.8 26 2 DEATH <15 15 - 30 
20 44 MALE YES NO DIABETIC 150 8.7 28 8 ALIVE <15 15 - 30 
21 53 MALE YES YES DIABETIC 150 7.8 50 10 ALIVE <15 30 - 50 
22 59 MALE NO YES DIABETIC 165 8.3 48 12 ALIVE <15 30 - 50 
23 62 MALE YES NO DIABETIC 138 7.1 35 8 ALIVE <15 30 - 50 
24 45 MALE YES NO DIABETIC 172 8.3 33 20 ALIVE >15 30 - 50 
25 56 MALE NO YES DIABETIC 156 7.8 34 16 ALIVE >15 30 - 50 
26 64 FEMALE NO NO DIABETIC 139 7.6 36 20 ALIVE >15 30 - 50 
27 70 MALE YES NO DIABETIC 171 10.2 35 18 ALIVE >15 30 - 50 
28 59 MALE YES NO DIABETIC 164 8.4 34 16 ALIVE >15 30 - 50 
29 61 FEMALE NO NO DIABETIC 131 8.6 35 20 ALIVE >15 30 - 50 
30 48 MALE YES YES DIABETIC 166 7.8 34 18 ALIVE >15 30 - 50 
31 59 MALE YES NO DIABETIC 198 9.2 37 16 ALIVE >15 30 - 50 
SL.NO AGE Sex SMOKER ALCOHOLIC Diabetic Status FBS 
mg/dl 
HBA1C 
% 
Lipo 
Protein 
(a) mg/dl 
MORBIDITY MORTALITY 
Scandi 
navian 
Score 
VAR 
32 64 MALE YES YES DIABETIC 181 10.2 37 18 ALIVE >15 30 - 50 
33 66 FEMALE NO NO DIABETIC 182 8.3 36 16 ALIVE >15 30 - 50 
34 63 FEMALE NO NO DIABETIC 186 7.8 40 18 ALIVE >15 30 - 50 
35 54 FEMALE NO NO DIABETIC 181 9.4 45 18 ALIVE >15 30 - 50 
36 49 MALE YES YES DIABETIC 206 8.6 40 18 ALIVE >15 30 - 50 
37 52 MALE YES YES DIABETIC 206 9.9 36 18 ALIVE >15 30 - 50 
38 59 MALE YES YES DIABETIC 204 8.3 45 16 ALIVE >15 30 - 50 
39 71 FEMALE NO NO DIABETIC 221 8.0 40 18 ALIVE >15 30 - 50 
40 49 MALE YES YES DIABETIC 201 7.8 48 18 ALIVE >15 30 - 50 
41 73 MALE NO YES DIABETIC 218 8.0 50 18 ALIVE >15 30 - 50 
42 67 FEMALE NO NO DIABETIC 200 7.4 44 16 ALIVE >15 30 - 50 
43 45 MALE YES YES DIABETIC 183 7.1 30 16 ALIVE >15 15 - 30 
44 65 FEMALE NO NO DIABETIC 205 8.4 39 16 ALIVE >15 30 - 50 
45 48 MALE YES YES DIABETIC 218 8.1 42 18 ALIVE >15 30 - 50 
46 73 MALE NO NO DIABETIC 184 8.3 37 20 ALIVE >15 30 - 50 
47 60 FEMALE NO NO DIABETIC 189 8.2 47 18 ALIVE >15 30 - 50 
48 58 MALE NO NO DIABETIC 212 8.5 46 14 ALIVE <15 30 - 50 
49 48 MALE YES NO DIABETIC 200 7.8 38 16 ALIVE >15 30 - 50 
50 65 MALE NO YES DIABETIC 196 8.2 34 8 ALIVE <15 30 - 50 
51 41 FEMALE YES YES NON DIABETIC 98 5.2 16 12 ALIVE <15 15 - 30 
52 62 MALE YES NO NON DIABETIC 112 6.0 17 8 ALIVE >15 15 - 30 
53 67 FEMALE NO NO NON DIABETIC 96 5.9 22 14 ALIVE <15 15 - 30 
54 43 MALE YES NO NON DIABETIC 116 5.5 16 6 ALIVE <15 15 - 30 
55 48 MALE NO NO NON DIABETIC 114 6.2 31 6 ALIVE <15 30 - 50 
56 43 FEMALE YES NO NON DIABETIC 121 6.0 31 14 ALIVE <15 30 - 50 
57 45 MALE NO NO NON DIABETIC 90 4.1 16 14 ALIVE <15 15 - 30 
58 47 FEMALE NO NO NON DIABETIC 87 6.5 21 10 ALIVE <15 15 - 30 
59 53 FEMALE NO NO NON DIABETIC 108 5.2 31 10 ALIVE <15 30 - 50 
60 69 FEMALE YES NO NON DIABETIC 115 6.0 32 6 ALIVE <15 30 - 50 
61 66 FEMALE YES NO NON DIABETIC 120 5.0 41 12 ALIVE <15 30 - 50 
62 50 FEMALE YES NO NON DIABETIC 117 5.3 47 6 ALIVE <15 30 - 50 
SL.NO AGE Sex SMOKER ALCOHOLIC Diabetic Status FBS 
mg/dl 
HBA1C 
% 
Lipo 
Protein 
(a) mg/dl 
MORBIDITY MORTALITY 
Scandi 
navian 
Score 
VAR 
63 50 FEMALE NO NO NON DIABETIC 95 5.3 42 20 ALIVE <15 30 - 50 
64 44 FEMALE YES NO NON DIABETIC 91 5.0 48 20 ALIVE <15 30 - 50 
65 59 MALE NO NO NON DIABETIC 87 5.2 40 16 ALIVE >15 30 - 50 
66 46 MALE NO NO NON DIABETIC 94 6.4 41 18 ALIVE >15 30 - 50 
67 44 MALE NO NO NON DIABETIC 81 4.1 47 2 DEATH >15 30 - 50 
68 40 MALE NO NO NON DIABETIC 107 6.4 38 18 ALIVE >15 30 - 50 
69 51 MALE NO NO NON DIABETIC 74 4.8 37 18 ALIVE >15 30 - 50 
70 60 MALE YES NO NON DIABETIC 97 5.1 47 18 ALIVE >15 30 - 50 
71 44 FEMALE YES NO NON DIABETIC 107 4.2 36 18 ALIVE >15 30 - 50 
72 41 FEMALE NO NO NON DIABETIC 95 4.2 32 18 ALIVE >15 30 - 50 
73 58 FEMALE YES NO NON DIABETIC 77 4.3 33 18 ALIVE >15 30 - 50 
74 68 MALE YES NO NON DIABETIC 67 5.7 31 16 ALIVE >15 30 - 50 
75 67 FEMALE YES YES NON DIABETIC 90 5.7 28 18 ALIVE >15 15 - 30 
76 43 MALE YES YES NON DIABETIC 100 6.3 26 18 ALIVE >15 15 - 30 
77 53 FEMALE YES NO NON DIABETIC 76 4.9 30 18 ALIVE >15 15 - 30 
78 64 FEMALE NO NO NON DIABETIC 100 4.8 22 16 ALIVE >15 15 - 30 
79 64 FEMALE YES NO NON DIABETIC 103 6.5 24 20 ALIVE >15 15 - 30 
80 63 MALE NO NO NON DIABETIC 75 6.2 33 18 ALIVE >15 30 - 50 
81 58 FEMALE NO YES NON DIABETIC 92 6.1 22 16 ALIVE >15 15 - 30 
82 63 FEMALE YES YES NON DIABETIC 99 4.1 30 16 ALIVE >15 15 - 30 
83 53 MALE NO YES NON DIABETIC 97 4.2 27 20 ALIVE >15 15 - 30 
84 41 MALE YES YES NON DIABETIC 66 5.2 32 2 DEATH >15 30 - 50 
85 61 MALE YES YES NON DIABETIC 107 6.5 29 14 ALIVE >15 15 - 30 
86 46 MALE NO NO NON DIABETIC 102 5.9 30 16 ALIVE >15 15 - 30 
87 48 MALE NO YES NON DIABETIC 69 4.2 25 18 ALIVE <15 15 - 30 
88 69 MALE YES NO NON DIABETIC 88 4.5 23 18 ALIVE >15 15 - 30 
89 49 MALE NO YES NON DIABETIC 77 6.3 34 18 ALIVE >15 30 - 50 
90 54 MALE YES NO NON DIABETIC 73 4.9 28 16 ALIVE >15 15 - 30 
91 54 MALE NO NO NON DIABETIC 87 6.2 20 18 ALIVE >15 15 - 30 
92 67 FEMALE YES YES NON DIABETIC 72 4.4 22 20 ALIVE >15 15 - 30 
  
SL.NO AGE Sex SMOKER ALCOHOLIC Diabetic Status FBS 
mg/dl 
HBA1C 
% 
Lipo 
Protein 
(a) mg/dl 
MORBIDITY MORTALITY 
Scandi 
navian 
Score 
VAR 
93 51 MALE NO NO NON DIABETIC 91 4.2 20 20 ALIVE >15 15 - 30 
94 54 MALE YES NO NON DIABETIC 92 5.6 21 18 ALIVE >15 15 - 30 
95 50 MALE NO YES NON DIABETIC 97 5.5 24 2 DEATH >15 15 - 30 
96 44 MALE NO NO NON DIABETIC 102 4.1 21 14 ALIVE >15 15 - 30 
97 54 MALE YES NO NON DIABETIC 109 6.3 22 16 ALIVE >15 15 - 30 
98 61 MALE YES NO NON DIABETIC 93 6.1 30 20 ALIVE <15 15 - 30 
99 47 MALE NO YES NON DIABETIC 83 5.4 34 4 ALIVE >15 30 - 50 
100 62 MALE YES YES NON DIABETIC 89 5.5 31 4 ALIVE >15 30 - 50 
 
